Repositioning Candidate Details

Candidate ID: R0647
Source ID: DB04919
Source Type: investigational
Compound Type: biotech
Compound Name: Alfimeprase
Synonyms: Alfimeprase
Molecular Formula: --
SMILES: --
DrugBank Description: Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (<i>Agkistrodon contortrix contortrix</i>). It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo.
CAS Number: 259074-76-5
Molecular Weight:
DrugBank Indication: Alfimeprase is being evaluated as a potential treatment for acute ischemic stroke, catheter occlusion (CO) and acute peripheral arterial occlusion (PAO).
DrugBank Pharmacology: Alfimeprase is a recombinant direct acting fibrinolytic (rDAF), or blood clot dissolver, that has the potential to rapidly and directly degrade fibrin, a protein that provides the scaffolding for blood clots, when delivered through a catheter to the site of a blood clot.
DrugBank MoA: When delivered locally at the site of a blood clot, alfimeprase has the potential, through a unique mechanism of action, to directly and rapidly degrade fibrin, a protein that provides the scaffolding for blood clots. In addition, alfimeprase's thrombolytic activity appears to be localized to the site of delivery because it is rapidly inactivated by alpha-2 macroglobulin, a naturally occurring protein in the blood, as it moves away from the site of delivery and into the general blood circulation.
Targets: Fibrinogen alpha chain; Fibrinogen beta chain
Inclusion Criteria: Indication associated